Market Cap
US$486.4m
Last Updated
2019/10/20 00:36 UTC
Data Sources
Company Financials +
Executive Summary
AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves.
Snowflake
Fundamentals
Excellent balance sheet with limited growth.
Similar Companies
Share Price & News
How has AxoGen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
6.0%
AXGN
1.9%
US Medical Equipment
0.4%
US Market
1 Year Return
-63.0%
AXGN
15.6%
US Medical Equipment
6.9%
US Market
Return vs Industry: AXGN underperformed the US Medical Equipment industry which returned 15.6% over the past year.
Return vs Market: AXGN underperformed the US Market which returned 6.9% over the past year.
Shareholder returns
| AXGN | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.0% | 1.9% | 0.4% |
| 30 Day | -12.4% | -1.7% | -1.1% |
| 90 Day | -34.1% | -0.03% | -0.5% |
| 1 Year | -63.0%-63.0% | 16.5%15.6% | 9.3%6.9% |
| 3 Year | 38.4%38.4% | 72.1%66.9% | 45.8%36.4% |
| 5 Year | 387.8%387.8% | 125.8%100.8% | 62.9%45.1% |
Price Volatility Vs. Market
How volatile is AxoGen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is AxoGen, Inc. (NASDAQ:AXGN) Overpaying Its CEO?1 month ago | Simply Wall St
We Think AxoGen (NASDAQ:AXGN) Can Afford To Drive Business Growth2 months ago | Simply Wall St
Chairman Karen Zaderej Just Bought Shares In AxoGen, Inc. (NASDAQ:AXGN)Valuation
Is AxoGen undervalued compared to its fair value and its price relative to the market?
3.53x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AXGN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: AXGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate AXGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AXGN is good value based on its PB Ratio (3.5x) compared to the US Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is AxoGen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
55.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AXGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AXGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AXGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AXGN's revenue (20.7% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: AXGN's revenue (20.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if AXGN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has AxoGen performed over the past 5 years?
-7.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: AXGN is unprofitable, and losses have increased over the past 5 years at a rate of -7.5% per year.
Accelerating Growth: Unable to compare AXGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AXGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: AXGN has a negative Return on Equity (-18.74%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: AXGN is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: AXGN is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is AxoGen's financial position?
Financial Position Analysis
Short Term Liabilities: AXGN's short term assets ($141.3M) exceeds its short term liabilities ($16.2M)
Long Term Liabilities: AXGN's short term assets (141.3M) exceeds its long term liabilities (2.4M)
Debt to Equity History and Analysis
Debt Level: AXGN is debt free.
Reducing Debt: AXGN currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Inventory Level: AXGN has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if AXGN's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AXGN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AXGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is AxoGen's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate AXGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AXGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if AXGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AXGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AXGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of AxoGen's salary, the management and board of directors tenure and is there insider trading?
1.3yrs
Average management tenure
CEO
Karen Zaderej (57yo)
8.1yrs
Tenure
US$3,665,188
Compensation
Ms. Karen Zaderej has been the Chief Executive Officer of AxoGen, Inc. since May 2010 and also has been its President since September 30, 2011. She has been Director of Viveve Medical Inc. since September ...
CEO Compensation Analysis
Compensation vs. Market: Karen's total compensation ($USD3.67M) is about average for companies of similar size in the US market ($USD1.79M).
Compensation vs Earnings: Karen's compensation has been consistent with company performance over the past year.
Management Age and Tenure
1.3yrs
Average Tenure
54.5yo
Average Age
Experienced Management: AXGN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Age and Tenure
6.1yrs
Average Tenure
58.5yo
Average Age
Experienced Board: AXGN's board of directors are considered experienced (6.1 years average tenure).
Insider Trading
Insider Buying: AXGN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 4,000 |
| Max Price | US$13.13 |
| Entity | Individual |
| Role | Senior Key Executive Chief Strategy & Business Development Officer |
| Shares | 5,635 |
| Max Price | US$15.12 |
| Entity | Individual |
| Role | Head of Human Resources Chief Human Resources Officer |
| Shares | 2,000 |
| Max Price | US$15.13 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 15,535 |
| Max Price | US$14.10 |
| Entity | Individual |
| Role | Chief Executive Officer Chairman |
| Shares | 75,000 |
| Max Price | US$13.50 |
| Entity | Individual |
| Shares | 5,000 |
| Max Price | US$20.25 |
| Entity | Individual |
| Shares | 20,000 |
| Max Price | US$22.63 |
| Entity | Individual |
| Role | Member of the Board of Directors General Counsel & Director |
| Shares | 20,000 |
| Max Price | US$32.25 |
| Entity | Individual |
| Role | Chief Executive Officer Chairman |
| Shares | 25,000 |
| Max Price | US$33.42 |
Ownership Breakdown
Management Team
Greg Freitag (57yo)
General Counsel & Director
- Tenure: 8.1yrs
- Compensation: US$856.65k
Pete Mariani (55yo)
Chief Financial Officer
- Tenure: 3.6yrs
- Compensation: US$1.44m
Karen Zaderej (57yo)
Chairman
- Tenure: 8.1yrs
- Compensation: US$3.67m
Eric Sandberg (54yo)
Chief Commercial Officer
- Tenure: 0.8yrs
Mike Donovan (54yo)
Vice President of Operations
- Tenure: 4.1yrs
Maria Martinez (51yo)
Chief Human Resources Officer
- Tenure: 1yrs
Kaila Krum
Vice President of Investor Relations & Corporate Development
- Tenure: 1.3yrs
Greg Davault (51yo)
Vice President of Marketing
- Tenure: 1.3yrs
Isabelle Billet (57yo)
Chief Strategy & Business Development Officer
- Tenure: 1yrs
John Glueck
Chief Compliance Officer & Assistant General Counsel
- Tenure: 1yrs
Board Members
Guido Neels (71yo)
Director
- Tenure: 4.2yrs
- Compensation: US$169.90k
Greg Freitag (57yo)
General Counsel & Director
- Tenure: 8.1yrs
- Compensation: US$856.65k
James Grooms (59yo)
Director
- Tenure: 8.1yrs
- Compensation: US$174.90k
Robert Rudelius (63yo)
Director
- Tenure: 9.1yrs
- Compensation: US$182.40k
Mark Gold (69yo)
Director
- Tenure: 8.1yrs
- Compensation: US$179.90k
Bruce Mast
Member of Board of Advisor
- Tenure: 0yrs
Karen Zaderej (57yo)
Chairman
- Tenure: 8.1yrs
- Compensation: US$3.67m
David Muir
Member of Board of Advisor
- Tenure: 0yrs
Quentin Blackford (40yo)
Director
- Tenure: 0.4yrs
Amy Wendell (58yo)
Lead Director
- Tenure: 1.4yrs
- Compensation: US$164.90k
Company Information
AxoGen, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: AxoGen, Inc.
- Ticker: AXGN
- Exchange: NasdaqCM
- Founded:
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$486.370m
- Shares outstanding: 39.26m
- Website: https://www.axogeninc.com
Number of Employees
Location
- AxoGen, Inc.
- 13631 Progress Boulevard
- Suite 400
- Alachua
- Florida
- 32615
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AXGN | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Oct 2011 |
| LT3 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2011 |
| 0HKD | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Oct 2011 |
Biography
AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerv ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/20 00:36 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.